OPERATIONALIZING BISPECIFIC T-CELL ENGAGER (BITE) THERAPY ADMINISTRATION IN THE AMBULATORY ONCOLOGY SETTING

被引：0
|
作者：
Hall, Nicole [1 ]
机构：
[1] Mt Sinai Hosp, New York, NY USA
来源：
ONCOLOGY NURSING FORUM | 2024年 / 51卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P90
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The Potential of Bispecific T-Cell Engager (BiTE®) in Cancer: Blinatumomab and More
    Klinger, M.
    ANNALS OF HEMATOLOGY, 2015, 94 (SUPPL 1) : 71 - 72
  • [2] Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer
    Stieglmaier, Julia
    Benjamin, Jonathan
    Nagorsen, Dirk
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (08) : 1093 - 1099
  • [3] The Potential of Bispecific T-Cell Engager (BiTE®) in Cancer: Blinatumomab and More
    Klinger, M.
    ANNALS OF HEMATOLOGY, 2015, 94 : S71 - S72
  • [4] The BiTE (Bispecific T-Cell engager) platform: development and future potential of a targeted immuno-oncology therapy across Tumor Types
    Einsele, Hermann
    Borghaei, Hossein
    Orlowski, Robert Z.
    Subklewe, Marion
    Roboz, Gail J.
    Zugmaier, Gerhard
    Kufer, Peter
    Iskander, Karim
    Kantarjian, Hagop M.
    CANCER, 2020, 126 (14) : 3192 - 3201
  • [5] Assessing ENPP3 as a renal cancer target for bispecific T-cell engager (BiTE) therapy
    Nolan-Stevaux, Olivier
    Fajardo, Flordeliza
    Liu, Lily
    Coberly, Suzanne
    McElroy, Patricia
    Nazarian, Aaron
    Bott, Franziska
    Nahrwold, Elisabeth
    Raum, Tobias
    Kischel, Roman
    Lutterbuese, Ralf
    Hoffmann, Patrick
    Kufer, Peter
    CANCER RESEARCH, 2016, 76
  • [6] Cardiovascular toxicities associated with bispecific T-cell engager therapy
    Sayed, Ahmed
    Munir, Malak
    Ghazi, Sanam M.
    Ferdousi, Mussammat
    Krishan, Satyam
    Shaaban, Adnan
    Habib, Alma
    Kola-Kehinde, Onaopepo
    Ruz, Patrick
    Khan, Sarah
    Sharma, Sneha
    Meara, Alexa
    Mahmood, Syed
    Feldman, Stephanie
    Yang, Eric H.
    Kim, Jiwon
    Epperla, Narendranath
    Addison, Daniel
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (02)
  • [7] Safety of Bispecific T-cell Engager Therapy in Autoimmune Disease
    Hagen, Melanie
    Bucci, Laura
    Boeltz, Sebastian
    Noethling, Danae-Mona
    Rothe, Tobias
    Raimondo, Maria Gabriella
    Tur, Carlo
    Wirsching, Andreas
    Wacker, Jochen
    Bozec, Aline
    Schett, Georg
    Grieshaber-Bouyer, Ricardo
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2299 - 2300
  • [8] Mechanisms of resistance to bispecific T-cell engager therapy for ovarian cancer
    Barakzai, Syem
    Xu, Mengyao
    Veillard, Irva
    Matoba, Yusuke
    Kononenko, Artem
    Kim, Eugene
    Bregar, Amy
    Eisenhauer, Eric L.
    Penson, Richard T.
    Bouberhan, Sara
    Colella, Tina
    Clark, Caroline
    Castro, Cesar Martin
    Spriggs, David R.
    Rueda, Bo R.
    Yeku, Oladapo O.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy
    Noguchi, Yoshihiro
    Yan, Miao
    Tachi, Tomoya
    Yoshimura, Tomoaki
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (04)
  • [10] Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule
    Pham, Elizabeth
    Friedrich, Matthias
    Aeffner, Famke
    Lutteropp, Michael
    Mariano, Natalie F.
    Deegen, Petra
    Dahlhoff, Christoph
    Vogel, Franziska
    Bluemel, Claudia
    Harrold, John M.
    Brandl, Christian
    Grinberg, Natalia
    Rattel, Benno
    Coxon, Angela
    Bailis, Julie M.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (10) : 1977 - 1987
12345